seed
Stage
About
Capsigen develops customized adeno-associated virus (AAV) capsids using its proprietary Transcription-Dependent Directed Evolution (TRADE™) platform to enable efficient and targeted delivery of gene therapies for various diseases.
Explore Capsigen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.